NCT03155425View on ClinicalTrials.gov

PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 9, 2017

Primary Completion Date

August 31, 2020

Study Completion Date

September 30, 2020

Conditions
Hodgkin Lymphoma, Adult
Interventions
DRUG

SHR-1210

A humanized monoclonal immunoglobulin

Trial Locations (2)

100142

Beijing Cancer Hospital, Beijing

210009

Jiangsu Cancer Hospital, Nanjing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03155425 - PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter